Core Viewpoint - Huason Pharmaceutical (002907.SZ) has received approval from the Chongqing Municipal Drug Administration for the re-registration of two pharmaceutical products: Glycyrrhizic Acid Ammonium and Sodium Ferulate Injection [1] Group 1: Product Approvals - The company has been granted a "Chemical Raw Material Drug Re-registration Approval Notice" for Glycyrrhizic Acid Ammonium, which is a raw material used for producing Glycyrrhizic Acid Ammonium Injection [1] - Additionally, the company received a "Drug Re-registration Approval Notice" for Sodium Ferulate Injection, which is used as an auxiliary treatment for ischemic cardiovascular and cerebrovascular diseases [1]

Core Viewpoint - Chongqing Huasen Pharmaceutical Co., Ltd. has received approval from the Chongqing Municipal Drug Administration for the re-registration of one chemical raw material (Dipotassium Glycyrrhizinate) and one drug (Sodium Ferulate Injection) [1] Group 1: Product Approvals - The re-registration approval includes a notification for the chemical raw material Dipotassium Glycyrrhizinate, which is used for the production of Glycyrrhizinate Injection [1] - The Sodium Ferulate Injection is indicated for the auxiliary treatment of ischemic cardiovascular and cerebrovascular diseases [1] Group 2: Impact on Operations - The re-registration approval will ensure the normal production and sales of the related drugs [1] - The company will strictly control product quality [1] - However, there is no significant short-term impact on the company's operating performance [1]

Core Viewpoint - Huason Pharmaceutical (002907.SZ) has received approval from the Chongqing Municipal Drug Administration for the re-registration of two pharmaceutical products: Glycyrrhizic Acid Dipotassium Salt and Sodium Ferulate Injection [1] Group 1: Product Approvals - The company has been granted a re-registration approval notice for Glycyrrhizic Acid Dipotassium Salt, which is a raw material used for producing Glycyrrhizic Acid Dipotassium Salt Injection [1] - The Sodium Ferulate Injection, which is used as an auxiliary treatment for ischemic cardiovascular and cerebrovascular diseases, has also received re-registration approval [1]